JPMorgan upgrades Corteva to Overweight after seed business spinoff
JPMorgan raised Corteva (CTVA) to Overweight from Neutral on October 6, 2026, setting a $19 price target for December 2027. The upgrade follows the company’s spin‑off of its seed business into Vylor, leaving a pure crop‑chemicals operation. JPMorgan’s lead analyst Jeffrey J. Zekauskas said the remaining business is undervalued, citing a gross margin of about 38% and negligible net debt.
Why it matters
The new $19 target implies roughly 53% upside from the October 5 close of $12.39, which could drive further buying pressure (JPMorgan’s note says). Investors will watch the upcoming standalone earnings report on November 11 for confirmation of the valuation thesis.
Key facts
- 1JPMorgan upgraded Corteva to Overweight from Neutral on October 6, 2026. tradingview.com
- 2The price target was set at $19 for December 2027. tradingview.com
- 3The target represents about 53% upside from Corteva’s October 5 closing price of $12.39. tradingview.com
- 4JPMorgan estimates the post‑spinoff business has a gross margin of about 38% and EBITDA margins of 16.5%‑17%. tradingview.com
- 5The company’s net debt is described as negligible. tradingview.com
- 6Corteva’s dividend yield is 5.04% with a payout ratio of 34% (GuruFocus). gurufocus.com
Summary written by AlphAI from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.